A Study of JNJ-53718678 in Participants With Hepatic Impairment
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate the pharmacokinetc (PK) of a single oral dose of
JNJ-53718678 in participants with varying degrees of impaired hepatic function (mild,
moderate, and severe) when compared with participants with normal hepatic function.